Shilpa Medicare Limited — JV/Acquisition, 05-03-2026: Amalgamation/Merger

Shilpa Medicare Ltd (SML) has received NCLT approval for the merger of its wholly-owned subsidiary, Shilpa Therapeutics Private Ltd. This strategic move aims to simplify the corporate structure and streamline operations, integrating a loss-making entity into the profit-making SML.

Since SML already holds 100% of Shilpa Therapeutics, no new shares will be issued, ensuring no dilution for existing SML shareholders. All shares of Shilpa Therapeutics will be cancelled as part of the amalgamation. The merger's appointed date is April 1, 2025, and it will become effective once the order is filed with the Registrar of Companies. Employees of the subsidiary will be absorbed by SML.